Severe Asthma Research Program - Wake Forest University

Wake Forest University87 enrolled

Overview

The mission of SARP is to improve the understanding of severe asthma through the integrated study of the effect of genetics on the clinical and biological features of asthma and to investigate how these change over time. The ultimate goal of these efforts is to promote better treatments for severe asthma.

The mission of the SARP is to improve the understanding of severe asthma to develop better treatments. The SARP will gain a better understanding of asthma and its endotypes, in children and adults, by defining the disease at the molecular and cellular levels in the context of the temporal phenotypic expression of the disease. To this end, the SARP investigators will utilize both mechanistic and evoked phenotype approaches to: 1) characterize developmental molecular, cellular and physiologic phenotypes in children and adults with mild to severe asthma, and 2) to further elucidate the evolving pathobiology and pathogenesis of severe asthma and its sub-phenotypes and 3) compare these features over time. This approach involves a shared longitudinal protocol conducted across all participating centers which includes common information on all SARP participants. Additionally, SARP investigators have each identified mechanistic research questions to be included in the shared longitudinal protocol. At Wake Forest University investigators are specifically interested in genetic influences on disease severity and the use of statistical modeling techniques to better understand disease phenotypes. Together, these longitudinal and mechanistic approaches will enable prediction of phenotype stability/fluctuation and pharmacologic responses and identification of novel, disease-modifying targets for treatment.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Asthma Severe Persistent Asthma

Eligibility

Sex: ALLMin age: 6 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Physician diagnosis of asthma, 2. Age 6 years and older 3. Evidence of historical reversibility, including either: * FEV1 bronchodilator reversibility ≥ 12%, or * Airway hyperresponsiveness reflected by methacholine PC20≤16 mg/mL. Exclusion Criteria: 1. No primary medical caregiver 2. Pregnancy (only if undergoing methacholine challenge or bronchoscopy) 3. Current smoking 4. Smoking history \> 10 pack years if ≥ 30 years of age or smoking history \>5 pack years if \< 30 years of age (Note: If a subject has a smoking history, no smoking within the past year) 5. Other chronic pulmonary disorders associated with asthma-like symptoms, including (but not limited to) cystic fibrosis, chronic obstructive pulmonary disease, chronic bronchitis, vocal cord dysfunction that is the sole cause of asthma symptoms, severe scoliosis or chest wall deformities that affect lung function, or congenital disorders of the lungs or airways 6. History of premature birth before 35 weeks gestation 7. Planning to relocate from the clinical center area before study completion

Locations (2)

Emory University

Atlanta, Georgia, United States

Wake Forest University Health Sciences

Winston-Salem, North Carolina, United States

Outcomes

Primary Outcomes

Change in pulmonary function over time

Pulmonary function test results include forced expiratory volume in one second (FEV1) and forced vital capacity (FVC).

Time frame: 36 months

Secondary Outcomes

Frequency of severe asthma exacerbations

Frequency of severe asthma exacerbations * Utilization of hospital based care (Emergency Department, Hospitalization, ICU) * Need for supplemental oral corticosteroids

Time frame: 36 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.